Bayer Health Care Pharmaceuticals Inc. won’t be facing consolidated federal litigation over its Mirena intrauterine device, a long-term method of birth control.
Consolidating litigation in which plaintiffs allege the Mirena IUDs caused abnormal elevation of cerebrospinal fluid in their skulls could have some benefit, but there are not enough cases to justify centralizing cases for pretrial purposes, wrote John G. Heyburn II, chairman of the U.S. Judicial Panel on Multidistrict Litigation.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
